



Universitätsklinikum Essen
Institut für Neuropathologie
Direktorin: Univ.-Prof. Dr. med. K. Keyvani

Sekretariat: (02 01) 723 3325
Fax: (02 01) 723 5927
Email: neuropathologie@uk-essen.de

(ADRESSETTE)

Patientenname:

Geburtsdatum:

☐

w

☐

m

Anforderungsschein Molekulare Diagnostik

Eingangs-Nummer (intern)

Patienten-Name/Vorname

Datum

Tumorzellgehalt (intern)

Anmerkungen

Arzt/Ärztin

ERREGERNACHWEIS

- ☐ HPV
- ☐ HCV
- ☐ Mycobacterien complex

VERSCHIEDENES

- ☐ IGH (Klonalität)
- ☐ TCR (Klonalität)
- ☐ BCOR-ITD
- ☐ 1p/19q FISH
- ☐ MGMT Promotor Methylierung
- ☐ miRNA PTC
- ☐ Microsatelliteninstabilität (MSI)
- ☐ Microsatellitenprofil

NGSEQUENZIERUNG

- ☐ **BRCA PANEL**
BRCA1 (1-24), BRCA2 (1-27)

- ☐ **HTS1 PANEL**
APC (1-16), DICER1 (1-28), PRKAR1A (1-11), PTEN (1-9), TSHR (1-10), WRN (2-35)

- ☐ **NPP1.0 PANEL**
ACVR1 (6-8), BRAF (11,15), CDKN2A (1-3), CDKN2B (1,2), CDKN2C (2,3), CIC (5,6,10,11,14,17,19,20), CTNNB1 (3,4,7,8,9), DICER1 (6,10,11,22,23,25,26,27), EGFR (2,7,8,15,18-21), FGFR1 (3,4,7,13,14,15,17), FUBP1 (1-20), H3F3A (2,3,4), H3F3B (2,3,4), HIST1H3B (1), HIST1H3C (1), HIST2H3C (1), IDH1 (3-10), IDH2 (1-10), KBTBD4 (3), MET (2,3,6,8,11,14,19), NFKBIA (1-6), NOTCH1 (3,6,7,8,9,26,34), NRAS (2,3,4), PDGFRA (5,7,12,14,18), PIC3CA (2,3,5,10,16,21), PIK3R1 (10,11,13,14), PTEN (1-9), RB1 (1-26), STK11 (1-9), TERT-Promotor, TP53 (2-11)

- ☐ **CCP3 PANEL**
BRAF (11,15), EGFR (18-21), ERBB2 (2,3,12,17,20,26), FGFR1 (3-7,10,12-15,17), FGFR2 Tr-A (6,8,10,11,13-15), FGFR2 Tr-B (8,9,12,18), FGFR3 (3,6,7,9,10,12,14,16,18), HRAS (2-4), IDH1 (4), IDH2 (4), KIT (9,10,11,13,14,17,18), KRAS (2-4), MET (3,8,11,14,19), NRAS (2-4), PDGFRA (12,14,18), PIK3CA (3,5,8,10,16,21), RET (7,10,11,13-16), STK11 (1-9), TERT-Promotor, TP53 (2-11)

- ☐ **MAPK0 PANEL**
Gesamter codierender Bereich von BRAF, GNA11, GNAQ, KRAS, MAP2K1, MAP2K2, NRAS

■ MAPK1 PANEL

AKT1, AKT2, ARID1A, ARID1B, ATM, BAP1, BCLAF1, BRAF (11,15), BRCA1, BRCA2, CRAF, EGFR (18,19,20,21), ERBB2 (5,6,15,20,23,29), GNA11, GNAQ, GNAS, IDH1 (4), IDH2 (4), KDM6A, KIT (9,10,11,13,17,18), KRAS (2,3,4), MAP2K1, MAP2K2, MAPK1, MAPK3, MDM2, MET (3,8,11,14,19), MLH1, MSH2, NF1, NRAS (2,3,4), PALB2, PBRM1, PDGFRa (12,14,18), PIK3CA (3,5,10,16,21), PTEN, RNF43, RPA1, SF3B1 (14,15,16), SMAD4, SMARCA2, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

■ NNGML1 PANEL

ALK (22-25), BRAF (11,15), CTNNB1 (3), EGFR (18-21), ERBB2 (8,19,20), FGFR1 (4-7,10,12-15), FGFR2 (Transcript A:6-15,18; Transcript B: 8), FGFR3 (3,6,7,9,10,12,14,16,18), FGFR4 (3,6,9,12,13,15,16), IDH1 (4), IDH2 (4), KRAS (2-4), MAP2K1 (2,3), MET (14, 16-19), NRAS (2-4), PIK3CA (10,21), PTEN (1-8), ROS1 (34-41), TP53 (4-8)

GENFUSIONSPRODUKT-NACHWEIS

■ ARCTL PANEL

Auf Fusionen untersuchte Gene (*Exone in Klammern*):

ALK (2, 4, 6, 10, 16-23, Intron 19), AXL (18-20), BRAF (7-11), CCND1 (1-4), FGFR1 (2, 8-10, 17), FGFR2 (2, 5, 7, 8-10, 17), FGFR3 (3, 5, 8-10, 17, Intron 17), MET (2, 4-6, 13-17, 21), NRG1 (1-3, 6), NTRK1 (2, 4, 6, 8, 10-13), NTRK2 (5, 7, 9, 11-17), NTRK3 (4, 7, 10, 13-16), PPARG (1-3, 5), RAF1 (4-7, 9-12), RET (2, 4, 6, 8-14), ROS1 (2, 4, 7, 31- 37), THADA (24-30, 36, 37)

■ ARSAR 2 PANEL

Auf Fusionen untersuchte Gene (*Exone in Klammern*):

ALK (19-22), BCOR (6-8,12,14,15), CAMTA1 (8-10), CCNB3 (2-6), CIC (19,20), EPC1 (9-11), EWSR1 (4-13), FOXO1 (1-3), FUS (4-11,14), GLI1 (4-7), HMGA2 (1-5), JAZF1 (2-4), MEAF6 (4,5), MKL2 (11-13), NCOA2 (11-14), NTRK1 (2, 4, 6, 8, 10-13), NTRK2 (5, 7, 9, 11-17), NTRK3 (4, 7, 10, 12-16), PAX3 (6-8), PDGFB (2,3), PLAG1 (1-4), ROS1 (2, 4, 7, 31-37), SS18 (4-6, 8-11), STAT6 (1-7, 16-19), TAF15 (5-7), TCF12 (4-6), TFE3 (3-6), TFG (4-7), USP6 (1-3), YWHAE (5)

■ KIAA1549-BRAF-GENFUSIONSPRODUKT-NACHWEIS

SEQUENZIERUNG SANGER

■ ALK (20-25)	■ HFE (1,4)	■ PIK3CA (10,21)
■ BRAF (11,15)	■ HIST1H3B (1)	■ PTEN (1-9)
■ CTNNB1 (3)	■ IDH1 (4)	■ RET (10,11,13-16)
■ DDR2 (15-18)	■ IDH2 (1)	■ TP53 (4-9)
■ EGFR (18-21)	■ KIT (9,11,13,17)	■ TERT-Promotor
■ GNAS1 (7,8)	■ KRAS (2-4)	
■ H3F3A (2)	■ NRAS (2-4)	
■ H3F3B (2)	■ PDGFRa (12,14,18)	

IN SITU HYBRIDISIERUNG

■ ALK Break Apart	■ EWS Break Apart	■ NTRK2 Break Apart
■ BRAF Break Apart	■ FGFR1 Amplifikation	■ NTRK3 Break Apart
■ BCL2 Break Apart	■ FGFR2 Amplifikation	■ PHF1 Break Apart
■ BCL6 Break Apart	■ FOXO1 Break Apart	■ PIK3CA Amplifikation
■ BCR-ABL1 Fusion	■ FUS Break Apart	■ RB1 Deletion/Amplifikation
■ CDKN2A/B Deletion/Amplifikation	■ HER2 (ERBB2) Amplifikation	■ RET Break Apart
■ CIC Break Apart	■ JAZF1 Break Apart	■ ROS1 Break Apart
■ MET Amplifikation	■ MDM2 Amplifikation	■ SS18 (SYT) Break Apart
■ COL1A1 Break Apart	■ MYC Amplifikation	■ TFE3 Break Apart
■ COL1A1/PDGFRb Fusion	■ MYC Break Apart	■ USP6 Break Apart
■ CFS1R Break Apart	■ MYCN Amplifikation	■ VHL Deletion (LOH)
■ DDIT3 Break Apart	■ NR4A3 Break Apart	■ WWTR1 Break Apart
■ EGFR Amplifikation	■ NTRK1 Break Apart	■ YWHAE Break Apart

■ 850K-METHYLIERUNGSANALYSE

■ ANDERE UNTERSUCHUNGEN: